The US orphan drug programme 1983-1995 by Shulman, S R, Manocchia, M

Get full text

Pharmacy benefit management companies (PBMs). Why should we be interested? by Shulman, S R

Get full text

Introduction: Off-Label Uses and High-Cost Drugs: Promotion and Reimbursement Issues by Shulman, Sheila R., Hewitt, Peg

Get full text

Public Health and the Law: The Broader Message of Accutane by Shulman, Sheila R

Get full text

The Food and Drug Administration's Early Access and Fast-Track Approval Initiatives: How Have They Worked? by Shulman, Sheila R., Brown, Jeffrey S.

Get full text

The broader message of accutane by SHULMAN, S. R

Get full text

Determining Appropriate Reimbursement for Prescription Drugs: Off Label Uses and Investigational Therapies by Raiford, Drusilla S., Shulman, Sheila R., Lasagna, Louis

Get full text

The Drug Export Amendments Act of 1986: Is It All It Was Intended To Be? by Shulman, Sheila R., Manocchia, Michael, Seibring, Mark

Get full text

Clinical Practice Guidelines and Malpractice Law: An Evolving Standard of Care by Shulman, Sheila R.

Get full text

Implementation of the Orphan Drug Act: 1983-1991 by Shulman, Sheila R., Bienz-Tadmor, Brigitta, Seo, Pheak Son, DiMasi, Joseph A., Lasagna, Louis

Get full text

The 1987 Canadian Patent Law Amendments: Revised Pharmaceutical Compulsory Licensing Provisions by Shulman, Sheila R., Richard, Barbara W.

Get full text

Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia by SHULMAN, Nancy, ZOLOPA, Andrew, KEMPF, Dale J, SUN, Eugene, HAVLIR, Diane, HSU, Ann, RENZ, Cheryl, BOILER, Sheila, PING JIANG, RODE, Richard, GALLANT, Joel, RACE, Elizabeth

Get full text

Five-Year Findings of the Hypertension Detection and Follow-up Program: Prevention and Reversal of Left Ventricular Hypertrophy with Antihypertensive Drug Therapy

Get full text